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ABSTRACT
EGFR and HER-2 are important targets but none of the monoclonal antibodies or 
small molecule tyrosine kinase inhibitors specific for the HER members has been approved 
for the treatment of patients with ovarian cancers. In some studies, co-expression of 
other growth factor receptors has been associated with resistance to therapy with the 
HER inhibitors. The aim of the present study was to determine the relative expression, 
cellular location, and prognostic significance of HER-family members, the EGFR mutant 
(EGFRvIII) c-MET, IGF-1R and the cancer stem cell biomarker CD44 in 60 patients with 
FIGO stage III and IV ovarian cancer. At cut off >5% of tumour cells with positive 
staining, 62%, 59%, 65% and 45% of the cases were EGFR, HER-2, HER-3 and HER-4 
positive, and 3%, 22% and 48.3% of the cases were positive for EGFRvIII, c-MET, and 
CD44 respectively. Interestingly, 23% co-expressed all four members of the HER family. 
On univariate analysis, only EGFR staining at >50% of tumour cells (HR = 3.57, p = 
0.038) and CD44 staining at 3+ intensity (HR = 7.99, p = 0.004) were associated with 
a poorer overall survival. EGFR expression (HR = 2.83, p = 0.019) and its co-expression 
with HER-2, HER-3, HER-2/HER-3, and c-MET were all associated with poorer disease-
free survival. Our results suggest co-expression of the HER-family members is common 
in Stage III and IV ovarian cancer patients. Further studies on the prognostic significance 
and predictive value of all HER family member proteins for the response to treatment 
with various forms of the HER inhibitors are warranted.
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INTRODUCTION
Despite major advances in our understanding of 
cancer biology and pathogenesis, cytoreductive surgery, 
platinum-based chemotherapy and targeted therapy, 
ovarian cancer remains as one of the world’s most 
aggressive and lethal types of gynecological cancer [1–6]. 
Worldwide, an estimated 238,700 women were diagnosed 
with ovarian cancer, and 152,000 died of the disease in 
2012 [7]. As there are currently no reliable screening 
methods and the early stages of the disease usually present 
no obvious symptoms, the great majority of ovarian 
cancer patients are diagnosed at advanced stages of the 
disease [8, 9]. While the five-year survival rate for ovarian 
cancer patients diagnosed at stage I and II of the disease 
is approximately 90% and 65% respectively, it reduces to 
around 33% and 18% for patients diagnosed at stage III 
and stage IV respectively [10, 11]. Moreover, in spite of 
initial chemo-sensitivity, most ovarian cancers acquire a 
drug-resistant phenotype, which in turn makes it largely 
a recurrent and incurable disease [6, 9, 12, 13]. These 
statistics highlight the urgent need for the identification 
of marker(s), which are important in the progression 
of ovarian cancer, for use in the early detection of the 
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disease, and for guiding treatment [14]. It is also important 
to develop novel, more effective and less toxic therapies 
for patients with ovarian cancer [9, 13, 15–17].
In the past three decades, increased expression 
or activation of the epidermal growth factor receptor 
(EGFR) family (also called ErbB/HER family) have been 
reported in a wide range of epithelial cancers, and in some 
studies have also been associated with a poorer prognosis 
and resistance to therapeutic options [18–22]. The HER 
family members includes, EGFR, HER-2, HER-3 and 
HER-4. Homodimersiation and heterodimerisation of the 
HER family members, as a result of ligand binding and 
or receptor mutation, results in the activation of several 
downstream cell signaling pathways and ultimately tumour 
cell proliferation, reduced apoptosis, tumour migration and 
invasion, as well as resistance to therapy [19, 22, 23]. To 
date, several types of HER inhibitors have been approved 
for the treatment of patients with a wide range of epithelial 
cancers including the anti-EGFR monoclonal antibodies 
(mAbs) cetuximab, panitumumab, necitumumab and 
nimotuzumab, anti-HER mAbs trastuzumab, pertuzumab 
and ado-trastuzumab emtansine, and small molecule 
tyrosine kinase inhibitors (TKIs) such as EGFR specific 
erlotinib and gefitinib, dual EGFR/HER-2 TKI lapatinib, 
and pan HER-family TKIs afatinib and neratinib [24–26]. 
Despite these advances, many patients simply do not 
respond or eventually develop resistance to therapy with the 
EGFR inhibitors, and none of the HER inhibitors have yet 
been approved for the treatment of ovarian cancer patients 
[27–34]. In some studies, tumour heterogeneity, expression 
of other members of the HER family (e.g. HER-3), 
mutation of a HER family member (e.g. the EGFRvIII), the 
co-expression of other heterologous growth factor receptors 
(e.g. c-MET, IGF-1R), and the presence of cancer stem cells 
has been suggested as possible mechanisms of resistance 
to therapy with the HER inhibitors and cytotoxic drugs. 
These together with poor patient selection may therefore 
have contributed to the disappointing clinical trials with the 
HER inhibitors in ovarian cancer [35–43]. 
We have recently studied the impact of the growth 
factor receptor expression and the putative ovarian cancer 
stem cell marker CD44 on the sensitivity of a large panel of 
human ovarian cancer cells to treatment with various forms 
of HER-TKIs (Gefitinib, Erlotinib, Lapatinib, Sapitinib, 
Afatinib, Canertinib, Neratinib) and other TKIs including 
crizotinib (C-met/Alk inhibitor), NVP-AEW541 (IGF-1R 
inhibitor), dasatinib (v-abl/src/c-KIT TKI) and imatinib 
(v-abl/c-KIT/PDGFR TKI) [33]. Of the HER inhibitors, 
the irreversible pan-HER TKIs were found to be the most 
effective for inhibiting the growth and migration of ovarian 
cancer cells. However, to our knowledge, there is currently 
no comprehensive study on the relative expression, cellular 
location and prognostic significance of all members of the 
HER family, c-MET, IGF-1R, and the putative ovarian 
cancer stem cell biomarker in patients with ovarian cancer. 
Therefore, in this study we examined the relative expression 
and cellular location of all members of the HER family, the 
type-III mutated form of EGFR (EGFRvIII), c-MET, IGF-
1R and CD44 by immunohistochemistry in patients with 
FIGO stage III and IV ovarian cancer and their associations 
with clinico-pathological parameters, overall survival and 
disease-free survival.
RESULTS
Clinicopathological characteristics
Patient clinicopathological characteristics are 
summarised in Table 1. The mean overall survival in 
this study was 2.62 ± 1.7 years (median 2.3 years), and 
the mean disease-free survival was 25.2 ± 20 months 
(median 18 months). No association was found with the 
clinicopathological characteristics and overall survival of 
these patients. However, overall survival was found to be 
poorer in the eight patients who received bevacizumab 
(p = 0.021, Table 1) 
Most ovarian cancer cases were HER 
positive but EGFRvIII negative by 
immunohistochemistry 
The expression pattern of EGFR, HER-2, HER-3 
and HER-4 was determined in 60 FIGO stage III and IV 
ovarian tumour specimens. At a cut-off value of above 
5% of tumour cells with positive immunostaining, the 
expression of EGFR was seen in 37/60 (61.7%) ovarian 
cancer cases (Table 2). Of these, the cellular location 
of EGFR staining was membranous and cytoplasmic in 
20/60 (33.3%), and 17/60 (28.3%) of the cases examined 
respectively, and the intensity of EGFR staining of 2+ or 
3+ was present in five patients (Table 2, Figure 1). The 
great majority of tumour specimens (93%) were HER-
2 positive at the cut-off value of above 5%. However, 
in contrast to EGFR, the cellular location of HER-2 
immunostaining was predominantly cytoplasmic (50/60, 
83.3%) (Table 2, Figure 1). Interestingly, using the RTJ.2 
mAb the cellular location of HER-3 was mostly nuclear 
and of these, at cut-off value of above 5% of tumour cells 
with positive immunostaining was detected in 39/60 (65%) 
of the cases examined (Table 2, Figure 1). At the same 
cut-off value of above 5% of tumour cells with positive 
immunostaining, HER-4 expression was detected in 
27/60 (45%) of the cases examined, with the predominant 
location of immunostaining being cytoplasmic (43%) 
(Table 2, Figure 1). Finally, the expression of EGFRvIII 
was rare in tumour specimens from these patients and only 
weak cytoplasmic staining was seen in 3.3% (2/60) of the 
ovarian cancer cases examined (Table 2, Figure 1). The 
percentage of positive tumour specimens, at other cut-
off values (i.e. above 10%, 20% or 50% of the tumour 
cells with positive immunostaining) are summarised and 
presented in Table 2. 
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Expression level of IGF-1R, c-MET and CD44 
determined by immunohistochemistry
Next, we examined the expression pattern of other 
growth factor receptors (c-MET and IGF-1R) and one of 
the putative ovarian cancer stem cell markers, CD44, in 
tumour specimens from these patients. Interestingly, while 
the anti-IGF-1R Clone 24–31 mAb stained the IGF-1R 
positive control placenta, none of the 60 ovarian cancer 
specimens were IGF-1R positive (Table 2, Figure 1). At 
Table 1: Clinicopathological characteristics and overall survival of FIGO stage III and IV ovarian cancer patients
Characteristics
Number 
of patients 
(%)
Overall survival 
in years  
(mean ± SE)
p- value
Disease free survival 
in months  
(mean ± SE)
p- value
Age in years
≤ 65
> 65
22 (36.7)
38 (63.3)
4.6 ± 0.2
4.8 ± 0.2
NS 31.2 ± 5.7
46.3 ± 5.1
NS
Subtypes
Serous
Non-serous
51 (85)
9 (15)
4.7 ± 0.2
5.1 ± 0.4
NS 42.8 ± 4.2
23.0 ± 9.2
NS
FIGO stage
III
IV
44 (73.3)
16 (26.7)
4.8 ± 0.3
4.5 ± 0.1
NS 42.1 ± 4.8
35.1 ± 5.3
NS
Grade
G2
G3
2 (3.3)
58 (96.7)
NS NS 20.0 ± 0.0
41.2 ± 4.1
NS
Bevacizumab treated*
Yes
No
8 (13.3)
49 (81.7)
4.3 ± 0.1
5.0 ± 0.2
0.021 45.4 ± 6.5
37.7 ± 4.6
NS
NS: not significant (P > 0.05), 
*data for bevacizumab treated missing in 3 patients. OS and DFS analysis was conducted by omitting the missing data.
Overall survival and disease free survival relative to the indicated features was determined by Kaplan-Meier analysis and 
the log-rank test. P-value of < 0.05 was considered significant.
Table 2: Expression of HER family members, c-MET, IGF-IR and CD44 determined by immunohistochemistry in 
FIGO stage III and IV ovarian cancer patients, data are presented based on the percentage of tumour cells with 
positive staining, the intensity of staining and the cellular location of staining
No. of positive tumours (%)
Scoring criteria EGFR HER-2 HER-3 HER-4 EGFRvIII c-MET CD44
Percentage of positive tumour cells (%)
>5 37 (61.7) 56 (93.3) 39 (65) 27 (45) 2 (3.3) 13 (21.7) 29 (48.3)
>10 29 (48.3) 55 (91.7) 37 (61.7) 17 (28.3) 0 7 (11.7) 11 (18.3)
>20 25 (41.7) 50 (83.3) 33 (55) 10 (16.7) 0 7 (11.7) 10 (16.7)
>50 12 (20) 44 (73.3) 18 (30) 3 (5) 0 5 (8.3) 4 (6.7)
Intensity
1+ 32 (53.2) 19 (31.7) 28 (46.7) 25 (41.7) 2 (3.3) 9 (15) 7 (11.7)
2+ 4 (6.7) 25 (41.7) 19 (31.7) 2 (3.3) 0 4 (6.7) 13 (21.7)
3+ 1 (1.7) 12 (20) 5 (8.3) 1 (1.7) 0 0 10 (16.7)
Sub-cellular localisation
Membranous 20 (33.3) 6 (10) 0 2 (3.3) 0 0 30 (50)
Cytoplasmic 17 (28.3) 50 (83.3) 0 26 (43.3) 2 (3.3) 13 (21.7) 0
Nuclear 0 0 40 (66.7) 0 0 0 0
All tumours were IGF-IR negative 
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Figure 1: Immunohistochemical staining of tumour specimens from patients with stage III and IV ovarian cancer. 
EGFR 2+/3+ membranous (A), HER-2 2+ membranous (B), HER-3 3+ nuclear (C) HER-4 2+ membranous (D) EGFRvIII 1+ cytoplasmic 
(E), c-MET 2+ cytoplasmic (F), CD44 3+ membranous (G), and negative control (H). Magnification x100.
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the cut of value of above 5% of the tumour cells with 
positive immunostaining, the expression of c-MET was 
detected in 13/60 ovarian cancer cases (21.7%) with 
its cellular location all being cytoplasmic (Table 2, 
Figure 1). The cellular location of CD44 staining was 
only membranous. At cut-off value of above 5% of tumour 
cells with positive immunostaining, 48% of the ovarian 
cancer cases were CD44 positive (Table 2, Figure 1). 
The percentage of positive cases at other cut-off values 
and based on the intensity of immunostaining for these 
biomarkers are summarised in Table 2. 
Co-expression of different members of the HER 
family in patients with ovarian cancer 
While various studies have examined and reported 
the expression level of the individual members of the 
HER family, the number of studies on the co-expression 
of these receptors are limited. Therefore, next the co-
expression of HER family members, c-MET, and CD44 
were analysed, and the results are summarised in Table 
3. For example, at cut of values of above 5% of tumour 
cells with positive staining, dual expression of EGFR/
HER-2, EGFR/HER-3 and EGFR/HER-4 were present at 
62%, 45%, and 28% of the cases examined respectively 
(Table 3). In addition, 43%, 23% and 28% of the cases 
had co-expression of EGFR/HER-2/HER-3, EGFR/
HER-3/HER-4 and EGFR/HER-2/HER-4 respectively. 
Interestingly, of the 60 cases examined, 23% had co-
expression of all four members of the HER family 
(Table 3). In 3% and 12% of the cases examined, the co-
expression of all four members of the HER family was 
also accompanied by expression of c-MET and CD44 
respectively (Table 3).
CD44 expression with 3+ intensity is associated 
with a poorer overall survival
The association between the expression level of 
HER family members, at different cut-off values, the 
intensity of staining and the cellular location of staining 
and overall survival were determined using the Kaplan-
Meier curves and log ranks-test. EGFR expression at 
>50% of tumour cells with positive EGFR immunostaining 
was associated with poorer overall survival (p = 0.020) 
(Figure 2A). When using univariate analysis, patients 
with EGFR expression at cut-off values of >50% had a 
hazard ratio of 3.6 (CI 1.07 – 11.85 p = 0.038, Table 4), 
however the expression of EGFR >50% did not remain as 
an independent prognostic factor in multivariate analysis 
after adjusting for other covariates used in this study (HR 
3.8, CI 0.95–15.6, p = 0.058, Table 4). No significant 
association was found between the expression of HER 
member’s at other cut-off values and the overall survival 
in these patients, and nor between EGFRvIII expression 
and the overall survival (data not shown). 
While there was no significant association between 
CD44 immunostaining at cut-off values >5%, >10% and 
>20% and overall survival, CD44 immunostaining of 3+ 
intensity at cut-off values of >5% of tumour cells was 
associated with poorer overall survival in these patients 
(3.66 ± 0.39 vs. 5.01 ± 0.20) (p <0.0001) (Figure 2A). 
Using univariate analysis, we found an 8 fold increased 
risk of poorer overall survival with the expression of CD44 
3+ intensity at >5% cut-off value (p = 0.004) and this 
remained an independent prognostic factor for survival in 
multivariate analysis in this study (p = 0.007, Table 4).
Impact of HER family members, c-MET and 
CD44 expression on disease-free survival 
Of all cut-off values used in this study, only the 
EGFR positive immunostaining at cut-off values of >5% 
and >10% of the tumour cells were significantly associated 
with a poorer disease-free survival (32.34 ± 4.88 
vs 53.79 ± 5.78 months, p = 0.014 Figure 2B) 
and (29.64 ± 4.86 vs 47.9 ± 5.05 months, p = 0.026, data 
not shown). There was no significant association between 
HER-2 positive immunostaining at all cut-off values 
and disease-free survival in these ovarian cancer cases. 
However, HER-4 positive immunostaining in >10% of 
the tumour cells was associated with a better disease-free 
survival (53.43 ± 6.50 vs. 36.0 ± 4.3 months, p = 0.042) in 
these patients (Figure 2B). 
Moreover, there was no significant association 
between the expression of c-MET alone at all cut-off 
values (>5%, >10%, >20% and >50%) and disease-free 
survival. Interestingly, at cut-off values >5% of the tumour 
cells with positive staining, the co-expression of EGFR/
HER-2, EGFR/HER-3, EGFR/c-MET, and EGFR/HER-
2/HER-3 were all associated with a poorer disease free-
survival in the univariate analysis (Figure 2B, Table 4). 
Using multivariate analysis, with the exception of EGFR/
c-MET co-expression, the co-expression of the HER-
family members remained independent prognostic factors 
of DFS in this study (Table 4). 
DISCUSSION
Ovarian cancer is a leading cause of death from 
gynaecological cancers [44, 45]. Most ovarian cancer cases 
are currently diagnosed at advanced stages of the disease 
(III and IV) with tumour recurrence and chemoresistance 
as the major causes of the treatment failure [16]. Therefore, 
there is an urgent need for the identification of biomarkers 
for use in the early diagnosis of ovarian cancer, determining 
prognosis, and predicting response to therapy [46]. 
Moreover, it is essential to develop more effective and less 
toxic targeted therapies for patients diagnosed with ovarian 
cancer [2, 9, 47].
In the past three decades, abnormal expression and 
increased activation of members of the HER family have 
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been reported in a wide range of human malignancies 
and of these EGFR and HER-2 are important therapeutic 
targets for treatment with several monoclonal antibody 
based products and different forms of the HER inhibitors 
in a wide range of cancers. However, clinical trials with 
the HER inhibitors in patients with ovarian cancer have 
been disappointing and none of the HER inhibitors has 
yet been approved for the treatment of patients with 
ovarian cancer. This may be due to the lack of studies 
examining the relative expression, cellular location, 
prognostic significance and predictive value of all 
members of the HER family proteins in patients with 
ovarian cancer [48–50]. Indeed, as trans–activation of the 
HER family members through hetero/homodimerization 
can contribute to tumourigenesis, and human cancers, 
including ovarian cancer are heterogeneous in nature, 
it is considered to be essential to determine the relative 
expression of all members of the HER family in patients 
with ovarian cancer [51]. Also the interaction between the 
HER family members and other tyrosine kinases may be 
another route for promoting oncogenic signaling pathways 
and maintaining cancer cell survival and proliferation. 
Therefore, in this comprehensive study for the first time 
to our knowledge, we investigated the co-expression and 
cellular location of all members of the HER-family, as 
well as the EGFRvIII, c-MET and IGF-1R, and putative 
CSC marker CD44 in 60 patients with FIGO stages III and 
IV. We also investigated their impacts on overall survival 
and disease-free survival.
Several studies examined the expression level of 
the individual member of the HER family in patients with 
ovarian cancer. The expression of EGFR, HER-2, HER-3 
and HER-4 reported in the literature for ovarian cancer 
exhibits wide variation ranging from 9–90%, 6.4–52%, 
16–69%, and 65–90% of the cases examined respectively, 
with EGFRvIII expression being rare [52–59]. In this 
study of 60 FIGO stage III and IV patients, the expression 
levels of the EGFR and HER-2 were determined by 
immunohistochemistry using mAb EGFR.113 and mAb 
3B5 respectively. At cut off value of >5% of tumours 
with positive staining, EGFR and HER-2 expression was 
detected in 62% and 93% of the ovarian cancer cases 
respectively (Table 2). Of these, the cellular location 
of EGFR staining was membranous and cytoplasmic in 
33% and 28% of the cases examined, whereas HER-2 
immunostaining was predominantly cytoplasmic (83.3%) 
with only 10% of the cases having membranous expression 
of HER-2 (Table 2). The results of a meta-analysis of 15 
studies involving 2471 patients with ovarian cancer for the 
EGFR expression found positive EGFR immunostaining 
in 6.2% to 72.6% (median 35%) of tumours, and in 
7 studies (63.6%) EGFR expression was found to be 
predictive of a poorer overall survival [60]. In the same 
study, the authors also carried out a meta-analysis of 20 
Table 3: Co-expression of HER family members, c-MET, and CD44 determined by immunohistochemistry in patients 
with FIGO stage III and IV ovarian cancer. The percentage was scored based on the cut of value of above 5% of 
tumour cells with positive staining
Markers No. of positive tumours (%) Markers
No. of positive tumours 
(%)
EGFR/HER-2 37 (61.7) HER-2/HER-4/C-MET 5 (8.3)
EGFR/ HER-3 27 (45) HER-3/HER-4/C-MET 3 (5)
EGFR/HER-4 17 (28.3) EGFR/HER-2/HER-3/C-MET 6 (10)
EGFR/HER-2/HER-3 26 (43.3) EGFR/HER-2/HER-4/C-MET 2 (3.3)
EGFR/HER-3/HER-4 14 (23.3) EGFR/HER-2/HER-3/HER-4/C-MET 2 (3.3)
EGFR/HER-2/HER-4 17 (28.3) EGFR/CD44 17 (28.3)
EGFR/HER-2/HER-3/HER-4 14 (23.3) HER-2/CD44 28 (46.7)
HER-2/HER-3 37 (61.7) HER-3/CD44 17 (28.3)
HER-2/HER-4 26 (43.3) HER-4/CD44 14 (23.3)
HER-3/HER-4 19 (31.7) EGFR/HER-2/CD44 17 (28.3)
EGFR/C-MET 8 (13.3) EGFR/HER-3/CD44 11 (18.3)
HER-2/C-MET 13 (21.7) EGFR/HER-4/CD44 9 (15)
HER-3/C-MET 9 (15) HER-2/HER-3/CD44 17 (28.3)
HER-4/C-MET 5 (8.3) HER-2/HER-4/CD44 13 (21.7)
EGFR/HER-2/C-MET 8 (13.3) HER-3/HER-4/CD44 9 (15)
EGFR/HER-3/C-MET 6 (10) EGFR/HER-2/HER-3/CD44 11 (18.3)
EGFR/HER-4/C-MET 2 (3.3) EGFR/HER-2/HER-4/CD44 7 (11.7)
HER-2/HER-3/C-MET 9 (15) EGFR/HER-2/HER-3/HER-4/CD44 7 (11.7)
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studies involving 3055 patients for the HER-2 expression 
and found positive immunostaining for HER-2 in 5% to 
57% (median 18%) of the cases examined, and 8 out of 20 
studies (40%) found HER-2 positivity to be of a significant 
predictor of overall survival in univariate analysis [60]. 
This wide variation in the expression level of HER family 
members is common in ovarian cancer and could be due to 
the use of various techniques, various antibodies employed 
for the immunohistochemical detection of such receptors, 
different scoring system, as well as different patient 
and population size. Unlike EGFR and HER-2, very 
few studies have been conducted on HER-3 and HER-4 
expression in ovarian cancers and in particular the co-
expression all four members of the HER family and their 
prognostic significance [61–63]. Of the 60 stage III and IV 
ovarian cases examined here, we found 65% and 45% to 
be HER-3 and HER-4 positive respectively. Interestingly, 
the predominant location of HER-3 and HER-4 staining 
were found to be nuclear (67%), and cytoplasmic (43%) 
respectively (Table 2). Nuclear expression of HER-3 has 
also been reported in other types of cancer and associated 
with increased risk of disease progression [64].
Interestingly, 23% of the cases had co-expression 
of all four members of the HER family and 43%, 23% 
and 28% of the cases had co-expression of three members 
of the HER family namely EGFR/HER-2/HER-3, EGFR/
HER-3/HER-4 and EGFR/HER-2/HER-4 (Table 3). When 
examined at different cut off values, only EGFR staining 
at >50% of tumour cells (HR = 3.57, CI = 1.07–11.85, 
p = 0.038) was associated with a poorer overall survival 
in univariate analysis and EGFR expression at >5% of 
tumour cells (HR = 2.83, p = 0.019) and its co-expression 
Figure 2: The impact of various biomarker expressions on the overall survival and disease free survival in patients 
with stages III and IV ovarian cancer. (A) Kaplan-Meier survival curves of the overall survival for the patients with EGFR staining 
in >50% of tumour cells, and CD44 staining of 3+ intensity in >5%. (B) Kaplan-Meier survival curves of the disease free survival for 
the patients with total expression of EGFR staining of >5% of tumour cells, HER-4 staining of >10% tumour cells, EGFR & HER-2 co-
expression >5% tumour cells, EGFR & HER-3 co-expression >5% tumour cells, EGFR & HER-2 & HER-3 co-expression >5% tumour 
cells, EGFR & c-MET co-expression of >5% tumour cells. A log-rank test value of P- <0.05 was considered statistically significant.
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with HER-2 (HR = 2.83, p = 0.019), HER-3 (HR = 2.48, 
p = 0.023), and HER-2/HER-3 (HR = 2.60, p = 0.016), 
were all associated with poorer disease-free survival 
(Table 4, Figure 2). While, at the cut off value of >5% of 
tumour cells with positive immunostaining, 48% and 22% 
the cases were CD44 and c-MET positive respectively, 
only CD44 immunostaining of 3+ intensity was associated 
with a poorer overall survival in both univariate and 
multivariate analysis, and the c-MET/EGFR co-expression 
(HR = 3.05, p = 0.019) was associated with a poorer 
disease-free survival (Table 4). Interestingly, only one 
other study to our knowledge, has determined the relative 
expression of all four HER family members and c-MET 
in tissue arrays from 202 tumours from ovarian cancer 
patients (172 FIGO stages I-IV and 30 stages unknown). 
They found membranous expression of EGFR, HER-2, 
HER-3, and c-MET in 25%, 35%, 76%, and 96% of the 
cases examined [65]. HER-4 was found to be positive in 
98% of the cases examined, where immunostaining was 
based upon membrane, cytoplasmic or nuclear staining. 
They did not find any significant association between the 
expression levels of these growth factor receptors and 
PFS in both univariate analysis and multivariate analysis 
[65]. More recently, Mehner and colleagues reported the 
result of immunohistochemical staining of EGFR in tissue 
microarrays from 488 ovarian cancer patients. They found 
while 90% of their tumor specimens had some EGFR 
staining and 53% had membranous staining, the EGFR 
staining alone was not of prognostic value [59]. Also, there 
is currently conflicting data on the prognostic significance 
of CD44 in patients with ovarian cancer. While CD44 
expression was associated with unfavorable prognostic 
outcome in FIGO III and IV ovarian cancer in one study 
[66], Zhang and colleagues reported no correlation 
between CD44 expression and prognosis in advanced 
stage ovarian cancer [67]. In another study involving 96 
patients with serous ovarian epithelial cancer stages IIB-
IVA, 49% of the cases were CD44 positive and this was 
associated with a statistically significant shorter DFS 
and overall survival in such patients (HR 6.8, 2–4-19.2 
p ≤ 0.001) [68]. The expression of aldehyde dehydrogenase 
(ALDH1), which is another putative ovarian cancer stem 
cell biomarker, has also been correlated with significantly 
lower progression free survival and the maintenance of 
Table 4: Univariate and multivariate analysis of the association between sub-categories of biomarkers in overall 
survival and the disease free survival
Overall Survival Univariate Multivariate
Hazard Ratio 95% CI P-value Hazard Ratio 95% CI P-value
EGFR >5% 1.15 0.41–3.21 0.787 (NS) 1.02 0.31–3.31 0.964 (NS)
HER-2 >5% 0.61 0.13–2.81 0.531 (NS) 0.41 0.07–2.19 0.298 (NS)
HER-3 >5% 0.43 0.16–1.30 0.146 (NS) 0.36 0.16–1.15 0.088 (NS)
HER-4 >5% 1.85 0.63–5.37 0.256 (NS) 0.26 0.59–6.55 0.266 (NS)
c-MET >5% 1.23 0.33–4.50 0.748 (NS) 1.10 0.29–4.21 0.883 (NS)
CD44 >5% 1.08 0.38–3.06 0.882 (NS) 1.12 0.39–3.24 0.823 (NS)
EGFR >50% 3.57 1.07–11.85 0.038 3.85 0.95–15.6 0.058 (NS)
CD44 >5% 3+ 7.99 1.96–32.55 0.004 9.23 1.82–46.7 0.007
Disease free survival
EGFR >5% 2.83 1.18–6.77 0.019 2.53 1.00–6.36 0.048
HER-2 >5% 1.73 0.40–7.36 0.455 (NS) 2.44 0.31–6.22 0.660 (NS)
HER-3 >5% 0.41 0.61–3.27 0.414 (NS) 1.39 0.64–3.63 0.341 (NS)
HER-4 >5% 0.45 0.19–1.07 0.073 (NS) 1.51 0.21–1.27 0.151 (NS)
c-MET >5% 1.45 0.61–3.45 0.398 (NS) 1.50 0.62–3.60 0.362 (NS)
CD44 >5% 0.87 0.40–1.86 0.721 (NS) 0.95 0.43–2.06 0.896 (NS)
EGFR >10% 2.40 1.07–5.37 0.032 2.44 1.06–5.60 0.035
EGFR + HER-2 >5% 2.83 1.18–6.77 0.019 2.53 1.00–6.36 0.048
EGFR + HER-3 >5% 2.48 1.13–5.42 0.023 2.69 1.15–6.28 0.021
EGFR + HER-2 
+HER-3 >5%
2.60 1.19–5.67 0.016 2.82 1.22–6.50 0.015
EGFR + c-MET >5% 3.05 1.20–7.75 0.019 2.65 0.96–7.31 0.059 (NS)
HR: Hazard ratio; 95% CI: 95% confidence interval; p-value < 0.05, NS: non-significant.
P-value of < 0.05 was considered significant.
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ovarian cancer cell like properties in ovarian cancer 
patients [69, 70], highlighting the importance of co-
targeting of ovarian cancer stem cells in combination with 
other therapeutics in ovarian cancer. Surprisingly, none 
of the 60 cases examined in our study was found to be 
IGF-1R positive. There are currently very few studies of 
IGF-1R in ovarian cancer patients. While an earlier study 
reported that of 80 ovarian cancer cases (FIGO I–IV), 
only 9 (11%) of patients were IGF-1R positive [71], more 
recent studies have shown that IGF-1R expression was 
high (>50%) particularly in high-grade ovarian cancer 
cases [72–74]. 
In summary, our results suggest that co-expression 
of two, three or all four HER-family members and CD44 
overexpression are common in patients with Stages III and 
IV ovarian cancers and that EGFR and CD44 expression 
at different cut off values may be of prognostic value. 
However, further investigations involving a larger group 
of ovarian cancer patients are warranted to confirm the 
prognostic value of co-expression of HER family members 
in patients with ovarian cancer. Moreover, as the targets for 
therapeutic interventions with monoclonal antibody-based 
products and small molecules HER TKIs are the HER 
family proteins and not HER genes, further examination 
of tumour specimens from ovarian cancer patients in 
clinical trials with various types of HER inhibitors are 
warranted. Such studies would help to determine whether 
the expression of all four HER proteins would be a more 
reliable predictive biomarker(s) for stratification of ovarian 
cancer patients who would benefit from therapy with 
various types of the HER inhibitors [46].  
MATERIALS AND METHODS
Patient information
Ethical approval was obtained from the Research 
and Development Committee of the Royal Surrey County 
Hospital for examination of tumour specimens from 
patients with ovarian cancer for use in this study. Sixty 
patients with FIGO stage III and IV ovarian cancer were 
included in this retrospective study. All patients had 
radical surgery and cycles of chemotherapy (paclitaxel, 
carboplatin and gemcitabine) and 8 patients received 
anti-VEGF mAb bevacizumab between 2009 and 2013. 
As only archived tumour specimens were included in this 
study, the ethics committee waived the need for patient 
consent and patient records/information were analysed 
anonymously. Those cases with no follow-up information, 
and poor or insufficient tumour blocks were excluded 
from this study. 
Immunohistochemistry
The following primary antibodies were used in this 
study: mouse anti-EGFR (1:10, Novacastra, UK), mouse 
anti-HER-2 (1:150, Insight Biotechnology, UK), mouse 
anti-HER-3 RTJ.2 (1:50, Insight Biotechnology, UK), 
rabbit anti-HER-4 (1:20, Fisher Scientific, UK), rabbit 
anti-EGFRvIII (1:150, Bioss Antibodies, UK), mouse anti-
IGF-1R (4 ug/mL, Merck Millipore, UK), mouse anti-c-
MET (1:500, Novacastra, UK) and mouse anti-CD44 
(1:40, DAKO, UK). Formalin-fixed paraffin-embedded 
(FFPE) sections of tumour specimens (3 µM) were cut in 
serial sections, and then subjected to antigen retrieval and 
incubation with primary antibodies as described previously 
by Khelwatty and colleagues [22]. The optimisation for 
HER-3 and IGF-1R staining was conducted using the 
MCF-7 (HER-3+) breast cancer cell line and tumour 
section of the placenta respectively. Staining of the slides 
was carried out on a Ventana Benchmark Ultra autostainer 
with the Ultra View DAB kit (Roche, UK). Following 
this, all slides were rehydrated and counterstained with 
haematoxylin, mounted and cover slipped. 
Scoring system
In this study, the immunostaining of the tumour 
sections were scored based on the percentage of tumour 
cells that had positive immunostaining at different cut-
off values (i.e. >5%, >10%, >20% and >50%) and the 
intensity of immunostaining (i.e negative 0, weak positive 
1+, moderate positive 2+ and strongly positive 3+). The 
immunostaining was also scored based on the cellular 
location of the antigen i.e. whether the staining was 
predominantly present in the membrane, cytoplasm or 
nucleus of the cells. Two independent trained observers, 
without prior knowledge of the clinicopathological 
parameters, conducted the scoring and any disparity in 
scoring was resolved by simultaneous reassessment of the 
staining by both observers. 
Statistical analysis
The Chi-Squared test (Pearson Chi-square) and 
Fisher’s exact test were used to investigate the association 
between immunohistochemistry score and patient 
clinicopathological data. Kaplan-Meier survival plots 
and log-rank tests were used to analyse the differences 
between the groups. The Cox-regression model was used 
to perform univariate and multivariate analyses. For the 
multivariate analysis age, FIGO stage, grade and serous 
subtype were used simultaneously as covariates for both 
overall survival and disease-free survival, and P≤0.05 was 
considered statistically significant. All statistical analysis 
were carried out using the PASW Statistics 23 (SPSS Inc), 
as described in our previous studies [22].
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